Long-term outcome in patients with intravitreal Anti-VEGF therapy for exudative amd;Langzeit-Verlauf bei Patienten mit intravitrealer Anti-VEGF Therapie für neovaskuläre AMD

Klinische Monatsblatter fur Augenheilkunde

Volumn 232, Issue 4, 2015, Pages 533-537

  Amstutz, C A ^a,b   Fleischhauer, J ^a   Zweifel, S ^a   Barthelmes, D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

angiogenesis inhibitors; cohort studies; macular degeneration; ranibizumab; retina; vascular endothelial growth factor A; wet macular degeneration

Indexed keywords

VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; RANIBIZUMAB; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ARTICLE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MALE; RETROSPECTIVE STUDY; VISION DISORDERS; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LONGITUDINAL STUDIES; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84928468612     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0035-1545673     Document Type: Article

References (8)

1. Gragoudas E. S., Adamis A. P., Cunningham E. T. et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration. N Engl J Med: 2004; 351 2805 2816
2. Brown D. M., Michels M., Kaiser P. K. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology: 2009; 116 57.e5 65.e5
3. Rosenfeld P. J., Brown D. M., Heier J. S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med: 2006; 355 1419 1431
4. CATT Research Group Martin D. F., Maguire M. G. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med: 2011; 364 1897 1908
5. Singer M. A., Awh C. C., Sadda S. et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology: 2012; 119 1175 1183
6. Rofagha S., Bhisitkul R. B., Boyer D. S. et al. SEVEN-UP Study Group Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology: 2013; 120 2292 2299
7. Group MPS Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol: 1991; 109 1109 1114
8. Gregori N. Z., Feuer W., Rosenfeld P. J. Novel method for analyzing snellen visual acuity measurements. Retina: 2010; 30 1046 1050